Benitec Biopharma Inc.
BNTC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001808898
No open-market purchases or sales by Benitec Biopharma Inc. insiders were filed in the last 90 days; 86 institutions reported holding it in 13F filings for Q2 2026, worth $443.3M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Benitec Biopharma Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 25 | 30 | +5 |
| Shares | 13.7M | 19.0M | +5.28M (+38.5%) |
| Value | $126.8M | $240.2M | +$113.4M (+89.4%) |
New holders (8)
Institutions that held Benitec Biopharma Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Infinitum Asset Management, LLC | 210,000 | $2.65M | 1.40% |
| MYDA Advisors LLC | 50,000 | $631.5K | 0.18% |
| 683 Capital Management, LLC | 35,817 | $452.4K | 0.04% |
| Susquehanna International Group, LLP | 24,772 | $312.9K | 0.00% |
| Qube Research & Technologies Ltd | 20,896 | $263.9K | 0.00% |
| State Street Corp | 16,090 | $203.2K | 0.00% |
| Citigroup Inc | 12,463 | $157.4K | 0.00% |
| Royal Bank of Canada | 173 | $2.00K | 0.00% |
Sold out (3)
Institutions that held Benitec Biopharma Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Armistice Capital, LLC | 60,000 | $551.4K |
| Acuta Capital Partners, LLC | 29,800 | $273.9K |
| Citadel Advisors LLC | 14,244 | $130.9K |